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In this paper, the authors’ review the applicability of the open-source GATE Monte Carlo simulation
platform based on the GEANT4 toolkit for radiation therapy and dosimetry applications. The
many applications of GATE for state-of-the-art radiotherapy simulations are described including
external beam radiotherapy, brachytherapy, intraoperative radiotherapy, hadrontherapy, molecular
radiotherapy, and in vivo dose monitoring. Investigations that have been performed using GEANT4
only are also mentioned to illustrate the potential of GATE. The very practical feature of GATE
making it easy to model both a treatment and an imaging acquisition within the same framework
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is emphasized. The computational times associated with several applications are provided to illus-
trate the practical feasibility of the simulations using current computing facilities. © 2014 American
Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4871617]
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1. INTRODUCTION
Monte Carlo (MC) simulation is widely recognized as an
essential method to study the physics of nuclear medicine,
radiology, and radiation therapy. The concepts of deposited
energy and absorbed dose are of particular interest for radio-
therapy applications1 and imaging applications involving ion-
izing radiations.2 In radiation therapy (RT), treatment plan-
ning requires an accurate assessment of the absorbed dose
distribution throughout the organs and tissues of interest.
This is true for a large variety of RT approaches (e.g., us-
ing photons, electrons, protons, carbon beams, radioisotopes)
with different delivery conditions (broad beam, pencil beam,
scanning, rotational, brachytherapy, and targeted radionuclide
therapy). In diagnostic imaging applications involving ioniz-
ing radiation, such as computed tomography (CT), positron
emission tomography (PET), or single photon emission to-
mography (SPECT), the assessment of the absorbed dose
is important to better analyze the risk-benefit of the pro-
cedure. Imaging and therapy are increasingly tied together:
cone-beam or portal imaging are associated with conventional
linac RT, CT acquisitions are performed during tomother-
apy, radiographs pairs are acquired during Cyberknife treat-
ments, and new imaging systems are developed for treatment
monitoring in hadrontherapy, such as hadron-PET,3, 4 prompt-
gamma (PG) cameras,5, 6 and interaction vertex imaging (IVI)
systems.7 As a result, there is a need for a MC simulation plat-
form supporting radiation transport modeling for (combined)
imaging and dosimetry applications.
Many MC simulation tools have been developed for imag-
ing (e.g., Refs. 8–10) or dosimetry (e.g., Refs. 11–16). At the
moment, GATE (Refs. 17 and 18) is the only open-source
MC simulation platform supporting the user-friendly simu-
lation of imaging, RT and dosimetry in the same environ-
ment. GATE is an application based on the GEANT4 toolkit:
GEANT4 manages the kernel that simulates the interac-
tions between particles and matter, and GATE provides addi-
tional high-level features to facilitate the design of GEANT4-
based simulations. GATE is developed by the OpenGate
collaboration19 and is a community-driven initiative, where
every user can access the source code20 and propose new fea-
tures.
GATE is potentially useful for a broad range of simula-
tions, including those where the absorbed dose is the princi-
pal observable. While GATE has been widely validated and
used for a large variety of PET and SPECT studies, there
are still a limited number of papers reporting its application
and reliability in the context of dosimetry. The purpose of
this paper is therefore to review the current status of GATE
for dosimetry-related applications based on published valida-
tion works. Source macros for five applications discussed here
(brachytherapy, external beam radiotherapy with photons/
electrons, molecular radiotherapy, and protontherapy) are pro-
vided as additional material for the interested readers. As
GATE is based on GEANT4, validated GEANT4 applications
related to dosimetry are mentioned as application fields where
GATE could be successfully used. Upcoming developments
in GATE regarding RT and dosimetry applications are also
discussed.
2. ABSORBED DOSE CALCULATION IN GATE
In this paper, we focus on the absorbed dose D, de-
fined as the deposited energy per unit mass of medium,
reported in units of gray (1 Gy = 1 J/kg). In MC sim-
ulations, the energy deposited in a volume Edep is usu-
ally expressed in eV (1 eV = 1.60217646 × 10−19J). It
can be converted to Gy by accounting for the volume of
interest and the density: D[Gy] = (Edep[eV] × 1.60217646
× 10−19 [J/eV])/(ρ[kg/cm3]/V [cm3]).
The absorbed dose D is a physical quantity and does not
reflect the biological effects of irradiation. However, D is the
first step toward the assessment of the biological impact of
radiation, both for stochastic and deterministic effects. GATE
is provided with a mechanism, named DoseActor, which
stores the absorbed dose in a given volume in a 3D matrix. In
terms of GATE macros, the dose actor has to be attached to
the volume of interest. The user can provide the matrix size
and the matrix position is defined within the coordinate sys-
tem of the monitored volume. Note that if the user defines a
matrix size larger than the attached volume, the absorbed dose
deposition occurring outside the volume but inside the matrix
will not be recorded. The actor calculates the deposited en-
ergy in MeV (Edep), the absorbed dose D in Gy, the number of
hits (a “hit” occurs each time a primary or secondary particle
makes a step in a volume, with or without energy deposition),
and the local statistical uncertainty according to Ref. 21. The
squared sums of Edep and D are also provided and can be used
to compute the statistical uncertainty when the simulation is
split into multiple jobs. Equation (1) defines the statistical un-
certainty εk at pixel k, with N being the number of primary
events, dk, i the deposited energy in pixel k at primary event i.
The absorbed dose can be calculated as dose-to-water, as tra-
ditionally performed in RT, and as dose-to-medium as in con-
ventional MC simulations.22, 23 The conversion is performed
on the fly by accounting for the relative stopping power and
the energy transferred via nuclear interactions in the specific
medium. Note that this conversion method may not be appro-
priate for some situations in brachytherapy24
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i
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During particle tracking, the deposited energy is summed
in the matrix for each step occurring in the attached volume.
The two endpoints of a step are called the PreStep point and
PostStep point. For a charged particle, a position is randomly
chosen along the step and the values are stored in the ma-
trix at that position. For a photon, when secondary particles
are not created because the energy is below the production
threshold, energy is deposited at the PostStep position. The
user has to make sure that the step length is not too large
with respect to the matrix sampling. The output can be stored
in mhd image file format, composed of a header file and a
raw data file. This file format can be handled by several open-
source image processing toolkits, such as ITK (www.itk.org)
and ImageJ (rsbweb.nih.gov/ij). The coordinate system of the
image (called “origin”) within the scene (named the “world”)
is recorded. It therefore allows for positioning the absorbed
dose matrix in relation to the attached volume for visualisa-
tion purposes. Other file formats, such as hdr (Analyze), txt,
and root (http://root.cern.ch), are also supported.
The insertion of CT data into GEANT4 was described in
Ref. 25. The influence of the calibration of the Hounsfield
Units (HU) into material and density has also been reported.26
In GATE, the user can manually assign a material to any HU
range or use the Schneider method27 based on a predefined
group of materials (24 by default). Two mixtures with the
same elemental composition but different densities are con-
sidered as two distinct materials. Each requires the computa-
tion of cross-section, stopping power, and other tables, which
can be a problem if too many materials are used. In Ref. 25,
the authors described a method to dynamically change the
density at run time but this technique is not yet available in
GATE. In GATE, the number of materials can be controlled
with the density tolerance parameter.28 It is used to split a ma-
terial into two materials when its corresponding HU range is
larger than the tolerance.
Variance reduction techniques (VRT) and the use of cuts to
speed up simulations are available within GATE. Production
cuts can be set for preventing secondary photons, electrons,
positrons, or protons to be generated if their energy is below
a user-defined threshold. Cuts are expressed in distance, thus
depending on the material, or in energy. Cuts can be set to
different values in different regions. Regarding VRT, splitting
and Russian roulette methods are available. User can choose
to use VRT only in selected situations by employing “filters.”
For example, selective bremsstrahlung splitting (SBS) is de-
scribed in Ref. 29. For photon tracking without modeling dose
deposits, fast fictitious interaction tracking is available.30 Par-
ticle tracking in voxelized geometry can also be accelerated
with region-oriented CT representation.28 Since the GATE
V6.2 release, a specific VRT option is provided to acceler-
ate absorbed dose calculations for low energy photons (from
1 keV to a few hundred keV) in the kerma approximation.31
This method is based on the track length estimator (TLE).32
Efficiency gains between 10 and 103 can be obtained depend-
ing on the simulated configuration. Two additional low en-
ergy photon VRT, force-detection,33 and exponential TLE,34
are currently being developed and will be available in future
GATE releases.
Finally, a GPU (graphical processing units) option of
the DoseActor is being developed by the OpenGATE
collaboration.35 With this option, particles within the attached
volume are no longer tracked by GEANT4 but by a specific
GPU process, highly reducing the simulation time. Although
there are currently certain limitations in the GPU implemen-
tation (photon and electron processes only, no observables
during the GPU tracking process), there is a significant im-
pact in the overall resulting computational efficiency. This
GPU option will be integrated within the GATE V7 version
supporting combined CPU and GPU calculations in various
applications.
3. APPLICATIONS
In this section, we present several types of dosimet-
ric applications of GATE: molecular radiotherapy (MRT),
brachytherapy, intraoperative radiotherapy (IORT), external
beam RT (EBRT), particle therapy, and in vivo absorbed dose
monitoring. We also mention dose-related applications that
have only been addressed with GEANT4 so far, but where
GATE, being based on the GEANT4 toolbox, could be poten-
tially used with success.
3.A. Molecular radiotherapy
3.A.1. Dose point kernel
The use of MC in targeted radionuclide therapy or molec-
ular radiotherapy has been first dedicated to the simulation of
dose point kernels (DPK), i.e., the radial deposition of energy
around a point source in a homogeneous medium,36 for exam-
ple, with EGS.37 Any radioactive volume can be considered
as a juxtaposition of independent point sources (superposition
principle). Therefore, in a homogenous medium, the variation
of absorbed dose with the distance from a point source is suf-
ficient to obtain, by convolution, the absorbed dose for any
radioactive distribution. This is the rationale for the compu-
tation of DPKs that are used intensively in radiopharmaceuti-
cal dosimetry.38 Interestingly, the simple assumptions (point
source, usually monoenergetic particles, energy scoring in
spherical shells, homogeneous material) make DPK results an
interesting benchmark for MC codes.39–41
An early application of GATE for electron DPKs is de-
scribed in Ref. 42. More recently, in Ref. 43 the authors stud-
ied the energy deposition for mono-energetic electrons using
GATE V6. Comparisons with EGSnrc and MCNP4C showed
good agreement for electrons with energies between 15 keV
and 4 MeV, as long as parameters were correctly set, a point
consistent with earlier observations.44 At the moment, DPK-
based algorithms are based on the assumption that the human
body is equivalent to water, without taking into account tis-
sue variations. The combination of DPKs with patient SPECT
or PET data can provide a fast absorbed dose calculation,
which takes into account patient specific anatomic informa-
tion. A fast algorithm was proposed in Ref. 45. GATE V6.1
has been used for extending the existing DPKs in more tis-
sues and for a variety of nuclear radio-isotopes. Specifically
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in Ref. 46, DPKs were generated using GATE V6.1 for
10 keV to 10 MeV electrons and various radionuclides (177Lu,
90Y, 32P, 111In, 131I, 125I, and 99mTc), for water, bone, and
lungs. A comparison between results and data from the liter-
ature obtained using different codes (MCNP, EGS, FLUKA,
ETRAN, GEPTS, and PENELOPE) showed a general agree-
ment within 6%. An additional DPK dataset was then gener-
ated for other radionuclides of interest (67Ga, 68Ga, 123I, 124I,
125I, 153Sm, 186Re, and 188Re). The conclusion is that cur-
rent MC codes—including GATE—now provide equivalent
results for “standard” situations, involving photon/electron
transport for energies of interest in nuclear medicine. The ap-
plication of DPKs in voxel-based geometries can be found in
the computation of “Dose Voxel Kernels” or “Voxel S Val-
ues,” i.e., input data suited for a convolution with voxel-based
activity estimate as obtained in digital imaging. Some work
using GEANT4 was also recently reported by Amato et al.47
with 3D arrays of 11 × 11 × 11 cubic voxels, 3 mm in size,
for several emitters of interest in nuclear medicine (32P, 90Y,
99mTc, 177Lu, 131I, 153Sm, 186Re, 188Re), further demonstrating
the potential of GATE for that kind of applications.
Alpha particle and low energy (Auger) electron targeted
therapy corresponds to the specific and challenging situa-
tion of cellular radiopharmaceutical dosimetry. GATE has not
been used for such applications so far, but GEANT4 has,48, 49
so GATE could support such applications. Moreover, another
GEANT4-based tool, GEANT4-DNA50 is being developed to
deal with very low energy radiation transport at the molecular
level.51
3.A.2. S values and absorbed dose calculations
MC codes are used to compute reference values for
dosimetry, most often in terms of the “mean absorbed dose
per decay,” i.e., the S value, or Dose Conversion Factor.52, 53
These values are then used to derive reference absorbed
dose values for nuclear medicine practice (ICRP 1987,
2008). This relies on the acceptance of reference geome-
tries described as anthropomorphic phantoms [ICRP 2009
(Ref. 54)]. The same approach can be used for preclini-
cal experiments where rodent models have been proposed
for radiopharmaceutical dosimetry.55 Alternatively, direct ab-
sorbed dose calculation can be performed for a specific geom-
etry/radiopharmaceutical distribution dataset. This is the basis
of patient-specific dosimetry.
Preclinical dosimetry. GATE has been used for preclin-
ical dosimetry56 to study the energy deposition from 18F-
labeled radiopharmaceuticals in mice. Four models were con-
sidered: a voxelized MOBY,57 using a 400 μm spatial sam-
pling, and three high-resolution models of bladder, femur, and
vertebra, with a spatial sampling of 50, 15, and 25 μm, respec-
tively. Absorbed dose per injected activity (mGy/MBq) was
computed for the various organs of interest for FDG, FLT, and
fluoride. Absorbed dose volume histograms were generated.
Using GEANT4 only, Keenan et al.55 assessed the impact
of various parameters (material definition/densities, fine sub-
organ segmentation for airways, bones, heart, and stomach)
on 18F S values.
A comparison of their results, 18F S values obtained for
the MOBY 30g Nude Mouse model with MCNPX 2.7a and
GATE V6.1, yielded very close results, with most relative
differences in S values below 5%.58 S value computation
for positron emitting radionuclides with MOBY2 phantom
(mouse/rat) using GATE V6.1 is ongoing.59, 60
Clinical dosimetry. Aside from an early presentation in
2006,61 clinical nuclear medicine dosimetry results using
GATE are recent. In Ref. 62, GATE was used to compute
specific absorbed fractions (SAF) for photon sources in se-
lected organs of a reference anthropomorphic model. The
Snyder mathematical model63 was digitized and sampled (2
× 2 × 3 mm) to generate GATE input files for photons
(10 keV to 1 MeV). Six sources of interest were considered:
kidneys, liver, lungs, pancreas, spleen, and adrenals. The re-
sults for self-irradiation are very close to values published in
Ref. 63, except for energies below 30 keV. The same trend
can be observed for cross-irradiation. It must be stressed that
early results published for the Snyder phantom were obtained
with simplifying assumptions and radiation transport was ad-
dressed with a methodology that has been markedly improved
since. Therefore, it is not clear if values presented in Ref. 63
should still be considered as a reference.
GATE calculations (S values and SAFs) performed on the
Zubal phantom (4 × 4 × 4 mm sampling) have been com-
pared with MCNP-4B and MCNPX published data.64–66 Al-
though fairly good agreement between the various datasets
was reported, some discrepancies were observed, especially
for very low S values where the associated statistical uncer-
tainty was high. In a further study, the relevance of process-
ing paired organs as a single entity for absorbed dose calcu-
lation was investigated. This work was performed using the
Zubal phantom67 and GATE V6 and concluded that paired
organs should be treated separately for absorbed dose calcu-
lations. Other GATE-based dosimetry work using the Zubal
phantom68 demonstrated the importance of accounting for the
dose volume histogram in addition to the mean and maximum
absorbed dose when investigating the dose-response relation-
ship in 131I-targeted radiotherapy. Another study69 compared
the results obtained on six healthy volunteers during a clini-
cal study evaluating a new 18F-labeled PET/CT brain tracer.
A patient-specific approach was employed using MCNPX 2.5
and GATE V6.1. The validation of MC calculations by com-
paring GATE and MCNPX results versus OLINDA S values
for 18F on a voxelized MIRD phantom was successful with
less than 8% relative difference for mean organ self-absorbed
doses. Figure 1 illustrates an absorbed dose distribution com-
puted with GATE in a mouse from a 131I source overlaid on
the mouse CT.
3.B. Brachytherapy
3.B.1. Context
Since the 1990s, MC simulations have played an increas-
ing role in the characterization of brachytherapy devices.70 A
dosimetry formalism for photon brachytherapy sources has
been proposed in 1995, revised in 2004 by the AAPM
Medical Physics, Vol. 41, No. 6, June 2014
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FIG. 1. Dose distribution (normalized to the maximum dose) overlaid on a
mouse CT, obtained from an 131I source.
Radiation Therapy Committee Task Group No. 43
(Ref. 71) and updated again in No. 186.72 MC simula-
tions were used to calculate the dosimetry parameters such
as the air kerma strength, radial absorbed dose function,
anisotropy function and absorbed dose rate constant in liquid
water. These simulations were validated by comparison with
measurements, and consensus datasets were proposed for
incorporation into brachytherapy treatment planning systems
(TPS). Some MC studies have demonstrated limitations of
the TG-43 formalism,73, 74 e.g., due to the effects of source
shielding, interseed attenuation, and tissue heterogeneity.
TG-186 provided guidance on the usage of model-based dose
calculation algorithms (MBDCAs), such as collapsed-cone
(CC) convolution, superposition convolution, MC methods,
and more recently grid-based Boltzmann solver (GBBS) to
simulate radiation transport in nonwater media. For beta
particle brachytherapy sources, the AAPM TG-60 formal-
ism is generally recommended to calculate the dosimetry
parameters.75, 76
3.B.2. GATE and GEANT4 studies
The only GATE application for brachytherapy involving
gamma sources has been reported by Thiam et al.77 who ex-
plored low energy 125I source dosimetry. The reported re-
sults agree with consensus values with a relative accuracy
better than 2%, suggesting the validity of GATE for such
applications. Yet, the potential of GATE for brachytherapy
application is mostly demonstrated by several studies re-
garding brachytherapy performed with the GEANT4 toolkit.
Figure 2 shows an example of a dose distribution for a low
dose rate brachytherapy treatment using 79 125I seeds.
Electromagnetic physics processes of GEANT4 at low en-
ergy (around few MeV) have been evaluated for brachyther-
apy in several publications. Several electromagnetic pack-
ages (standard, low energy, PENELOPE) and numerous pa-
rameters are available and recommendations have been pro-
vided. Some of those packages underwent changes between
versions. To assist users, GEANT4 and GATE integrate pre-
defined physics lists, i.e., preformatted setting of the physics
models and associated parameters for dosimetry purposes.
Among the GEANT4 studies, Granero et al.,78 compared
GEANT4 to the Plaque Simulator TPS for ocular brachyther-
apy treatment using eye plaques loaded with 125I radioac-
tive sources. They showed the lack of accuracy of the TPS
around the border of the eye. Pérez-Calatayud et al.79, 80
demonstrated that the standard electromagnetic package of
GEANT4 coupled with the low energy package for the
Rayleigh scattering gave reliable results for 137Cs sources.
All these packages are available in GATE and could thus be
used for similar simulations. Meigooni et al.81 obtained 5%
agreement between measured and simulated radial absorbed
dose and anisotropy functions. GEANT4 was also used to
model 192Ir sources.79, 82–85 Other dosimetric studies regard-
ing brachytherapy applicators in water have been performed
with GEANT4 (Refs. 86–89) and new candidates for treat-
ments have also been investigated, such as 57Co or 170Tm.90, 91
In Ref. 92, GEANT4 was used to characterize the x-ray source
of an electronic brachytherapy system and comparisons with
BEAMnrc simulations were reported. HVLs (half-value lay-
ers) and attenuation measurements obtained with the two
codes mostly agreed within uncertainty limits, while discrep-
ancies between simulations and measurements were observed
in the transverse plane.
Most simulations have been performed in water in this
brachytherapy context, in accordance with the TG-43 for-
malism. Yet, some recent studies focused on the influence of
variations in the elemental composition of human tissues.93, 94
User interfaces such as BrachyGUI (Ref. 95) and the AL-
GEBRA (ALgorithm for heterogeneous dosimetry based
FIG. 2. Dose distribution (normalized to the maximum dose) for a low dose rate brachytherapy treatment using 79 125I seeds. The Best Medical model 2301
125I source (Best Medical International, Springfield, VA.) has been simulated. The seed is made of a double-walled titanium capsule surrounding a tungsten
x-ray marker coated with an organic carbon layer impregnated with 125I.
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on GEANT4 for BRAchytherapy) platform96 have been
proposed.
Considering brachytherapy using beta sources, GATE was
shown to agree with EGSnrc within less than 3% in the maxi-
mum absorbed dose estimates between 50 keV and 4 MeV,
while pencil beam kernels agree within less than 4% be-
tween 15 keV and 20 MeV.43 These results suggest that with
an appropriate implementation of the electron multiple scat-
tering algorithms, reliable results are obtained. This is con-
trary to previously reported disagreements between results
obtained with GEANT4 using the low energy package (ver-
sion 4.1 and later) and with other well-validated MC codes
like PENELOPE.97 This seemingly contraditory results only
emphasize the fact that electron transport parameters should
be set very carefully. The PENELOPE package used for
GEANT4 simulations regarding electron brachytherapy90 is
included in the GEANT4 distribution and is thus available for
GATE simulations.
3.C. Intraoperative radiotherapy
The main objective of IORT is to perform radiother-
apy during surgery, directly after the removal of the tu-
mor, to reduce the probability of recurrence. As an exam-
ple, the INTRABEAMTM (Carl Zeiss Meditec, Oberkochen,
Germany) is a widely used IORT device. It is based on the
use of a 50 keV x-ray beam delivering nonfractionated doses
of 5–20 Gy. Different applicators can be attached to the
x-ray source in order to enable isotropic dose delivery de-
pending on the clinical application. For example, for breast
cancer treatment a single dose of 20 Gy is typically delivered
to every patient irrespective of individual tissue characteris-
tics or tumor location. A Monte Carlo dose planning system
based on GATE has been recently proposed for this device.98
GATE allowed for a detailed modeling of the system, includ-
ing the applicators for both breast cancer and kyphoplasty-
based IORT. For model validation, the depth-dose curve and
anisotropy function were measured in a water phantom specif-
ically designed for measuring the low energy x-ray source of
the system by means of a soft x-ray ionization chamber. These
measurements were compared with a GATE simulation of the
same water phantom. The depth-dose curve and anisotropy
function showed good agreement in water (<5%). A breast
cancer patient was also scanned by CT with the applica-
tor in place. In between the CT acquisition and the irradia-
tion, a number of thermoluminescent dosimeters (TLDs) were
placed on the patient skin at fixed distances around the appli-
cator. The CT scan was subsequently incorporated into the
proposed GATE based IORT dosimetry platform and doses at
the same location as those of the TLDs were compared to the
measured absorbed doses. The simulated and measured doses
were found equal to within 1% (considering 1 × 109 simu-
lated particles), suggesting that GATE can be reliably used
for such IORT treatment planning.
3.D. External beam radiotherapy
Dosimetric accuracy in advanced techniques of RT such as
IMRT, arc-therapy, CyberKnife, TomoTherapy, DMLC, and
others is necessary to ensure reliable patient treatment. MC
simulations have been extensively used in this field and in-
terested readers may, for example, refer to Ref. 99. Different
MC codes have been employed for modeling photon and elec-
tron based RT,1, 100–106 and the use of GATE in that context is
rather recent.
Specific tools such as absorbed dose scoring (DoseAc-
tor) and Phase-Space (PhS, PhaseSpaceActor) man-
agement were implemented within GATE V6 to facilitate the
use of GATE for modeling photon and electron based RT.
The first study performed with GATE V6 for EBRT demon-
strated the feasibility of simulating the whole RT experi-
ment within GATE.107 The different physical components of
an ELEKTA linear accelerator were simulated and the pro-
posed model was validated through a phantom-based dosime-
try study. Three major components were included in the pho-
ton fluence model: the target, the primary collimator, and the
flattening filter. The model was validated by comparing simu-
lations with various depth-dose and dose profiles measured in
water. Simulations and measurements in water agreed well,
with relative differences of 1% and 2% for depth-dose and
dose profiles, respectively. Gamma index comparisons led to
more than 90% of the points for all simulations within the
3%/3 mm gamma criterion.
In Ref. 108, a 6 MV photon beam linear accelerator
(Siemens Oncor Impression) was modeled and validated us-
ing percent depth-dose profile in water and tissue-equivalent
phantoms. Simulations and measurements were also com-
pared in terms of absolute and relative absorbed doses us-
ing IMRT dedicated quality assurance phantoms and patient
datasets. In the validation of the accelerator model, tissue-
phantom ratios obtained from GATE and from measurements
were 0.67 ± 0.063 and 0.68, respectively. In terms of percent
depth-dose and transverse profiles, discrepancies ranged from
0.04% to 0.1% and from 0.07% to 0.2%, respectively. When
comparing absolute absorbed doses between simulated and
measured beams based on the IMRT simulations using seven
patient datasets, GATE yielded a relative difference of 0.43%
± 0.25%. For the whole set of beams that were studied, the
mean gamma-index was 0.5 ± 0.152, and 90.8% ± 0.6% of
the measurement points satisfied the 5% criterion in absorbed
dose and the 4 mm criterion in distance criterion.
3.E. Particle therapy
As in conventional external beam therapy, MC simula-
tions in particle therapy are generally used to characterize
the treatment beam and compute absorbed dose distributions.
To the best of our knowledge, only few publications have
used GATE for beam line simulations in hadrontherapy to
date.
In Ref. 109, the authors compared GATE (based
on GEANT4 V9.2) to experimental measurements for a
100–203 MeV proton beam and reported a 0.3 mm range
and 1% dose accuracy. However, differences in transverse
profiles were up to 15%. Further investigations showed that
dose discrepancies of more than 8% were observed between
GEANT4 single and multiple scattering models suggesting
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FIG. 3. Absorbed dose distribution (arbitrary unit) of a proton treatment plan computed with GATE. The plan is composed of two fields (single field shown
here) with about 30 energy layers per field, with an energy range of 101–135 MeV, 1547 spots in total, and a spot sampling of 8 mm.
that GEANT4 tends to underestimate lateral absorbed dose
spreading. The authors also found that the GEANT4 precom-
pound model for inelastic hadronic collisions led to slightly
more accurate results than the Binary Cascade model.
In Ref. 29, the authors proposed a methodology to use
GATE V6.1 for modeling an IBA scanned proton beam
delivery system without beam line description, using only
measured data acquired for clinical commissioning. MC sim-
ulations were compared to measured data in various con-
figurations. Pristine Bragg peaks were reproduced to within
a 0.7 mm range and 0.2 mm spot size accuracy, while a
32 cm range SOBP with 10 cm modulation was reproduced to
within 0.8 mm range accuracy and a maximum point-to-point
dose difference of less than 2%. A 2D test pattern consisting
of a combination of homogeneous and high-gradient dose re-
gions passed a 2%/2 mm gamma index comparison for 97%
of the points. In Ref. 23, this model was used to compute the
absorbed dose distribution of a complete treatment plan that
was then compared to the one obtained with a commercial
TPS (XiO, Elekta). A satisfactory agreement was obtained
between XiO and GATE, with more than 95% of the points
passing a 2%/2 mm gamma evaluation. Yet, a maximum stop-
ping power difference of 3% was observed in human tissue of
0.9 g cm3 density and led to a range shift of 1–2 mm. Discrep-
ancies near heterogeneous regions (gas in the rectum) were
also observed. Figure 3 illustrates the dose distribution result-
ing from a proton treatment.
Before GATE was used for particle therapy applications,
many simulations regarding particle therapy and involving
GEANT4 were published, establishing the good adequacy
of this tool box in the particle therapy field. For example,
Paganetti et al.110, 111 used GEANT4 V5.2 to model and val-
idate the treatment nozzle of the Northeast Proton Therapy
Centre (NPTC), including an explicit model of the tempo-
ral variation of the beam energy by the range modulator
wheel.112 Since 2004, an official hadrontherapy GEANT4 ex-
ample is also available with the source code,113 describing the
62 MeV proton therapy beam line of the CATANA facility
(Centro di AdroTerapia e Applicazioni Nucleari Avanzate).
GEANT4 is also used in the VMCpro code dedicated to treat-
ment planning in proton beam therapy.114–116 GEANT4 was
also used to describe magnetic beam scanning for proton117
and carbon118, 119 compared a complete proton treatment plan
calculated with GEANT4 V9.3.p01 with that from a TPS. All
these contributions provide a solid background to support the
idea that GATE can play a significant role in particle ther-
apy applications in the future. Agreements between computed
dose and experimental measurements were usually very good,
with range accuracy to within a mm. Yet, discrepancies in lat-
eral dose spreading have been reported in several instances
and should be investigated carefully.
Recently, a dedicated package called TOPAS (Ref. 14) has
been described to simplify GEANT4 simulations of proton
therapy beam lines. The TOPAS and GATE platforms have
similar features and both rely on GEANT4. GATE is open
source, while TOPAS is not. TOPAS can efficiently define
proton beam lines, while GATE remains a more generic plat-
form and allows for an easy combined simulation of treat-
ments and imaging.
3.F. In vivo dose monitoring
3.F.1. Context
In particle therapy, in vivo imaging can be used to verify
the accuracy of the absorbed dose deposition inside the pa-
tient. To that end, 3D maps or 2D profiles of the location
of production of the fragmentation products (prompt gam-
mas, annihilation photons, secondary protons, etc.) are mea-
sured using an imaging system during or shortly after the
irradiation. Possible errors in dose delivery can then be de-
tected by comparing these measured maps with the expected
maps of emitted particles simulated based on the treatment
plan.120 These errors can be due to uncertainties in the con-
version from CT data to hadron interaction data, to mispo-
sitioning of the patient, to uncertainties in the beam fea-
tures, and/or to anatomical modifications (e.g., weight loss)
between the treatment plan calculation and the treatment
delivery.
Imaging-based methods of treatment delivery monitoring
heavily rely on simulated reference activity maps. This moni-
toring approach therefore strongly depends on the accuracy
of the MC codes used to calculate these reference maps.
As a result, several recent papers focused on the validation
of the MC codes used in this field, including FLUKA,13
GATE/GEANT4 (Refs. 17, 18, 121, and 122) and MCNPX.11
Here, we mostly discuss applications and results obtained
with GATE and possibilities offered by GEANT4.
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3.F.2. Hadron-PET studies
Among the imaging-based methods for particle therapy de-
livery monitoring, PET has already been tested clinically. Us-
ing PET, 511 keV photons resulting from the annihilation of
positrons produced by β+ emitters (mainly 11C, 10C, 150, and
13N) are detected and provide indirect information regarding
dose deposit within the patient.
In Ref. 123, the authors simulated with GATE a carbon ion
beam plan coupled with a complete PET ECAT EXACT HR+
system and demonstrated the need for simulating the full PET
system instead of only smoothing the simulated positron emit-
ter maps using a Gaussian function. Differences in the dis-
tal position of the signal fall-off of 20% were observed be-
tween the full PET system simulation and a simple convolu-
tion model. Robert et al.124 used GATE to compare five PET
system designs for inbeam treatment monitoring and showed
that patient mispositioning of the order of 2 mm could be de-
tected.
The relevance of GATE for these applications obviously
depends on the accuracy of the physics models describing
the hadronic interactions producing the β+ emitters that
yield the PET signal. Significant efforts have thus been ded-
icated to the assessment of the hadronic physics model ac-
curacy. In particular, Seravalli et al.125 compared β+ emit-
ter rates and profiles of depth production in a PMMA target
using GATE V6.1 (based on GEANT4 V9.2), FLUKA, and
MCNPX for proton irradiations. This study showed that, sim-
ilar to the FLUKA code,120 the GEANT4 internal hadronic
models used by GATE led to discrepancies when compared
to experimental PET results. An alternative method, consist-
ing in convolving the fluence of the protons with experimen-
tal cross-sections, was proposed by120 and implemented in
GATE.125 This latter study showed that when the same cross-
section datasets are used, the depth profiles and yields com-
puted by the three MC codes are comparable.
Other investigations of the accuracy of the hadronic
physics models in the context of particle therapy moni-
toring have been reported using GEANT4 only. In 2006,
Pshenichnov et al.126 compared the depth distributions of
positron-emitting nuclei produced in a PMMA target obtained
experimentally and by simulation. The total production rates
were also compared to the FLUKA and POSGEN MC codes.
The Binary Cascade model was used in the GEANT4 sim-
ulations. For protons and carbon ions, differences lower than
30% were observed between experimental and GEANT4 total
production yields for the most abundant β+ emitters, namely,
11C and 15O. In Ref. 127, several cross-section datasets avail-
able in the literature for the main reaction channels leading to
the β+ emitters production in protontherapy [160(p,pn)15O,
12C(p,pn)11C, 160(p,3p3n)11C] were investigated. Depending
on the cross-section values used for a tissue-equivalent mate-
rial, range differences up to 5 mm were observed for a 30 min
acquisition performed 15 min after the irradiation (off-line
imaging protocol). This study highlighted the need for new
experimental campaigns to better characterize cross-section
values in the energy ranges relevant to medical applications.
In Ref. 3, GEANT4 simulations using optimized cross-section
datasets as identified in Ref. 127 were employed to compare
inroom and offline PET experiments performed after two pa-
tient treatments (adenoid cystic carcinoma). In Ref. 128, the
accuracy of different hadronic models available in GEANT4
to predict experimentally measured β+ emitting isotopes and
prompt gamma-production rates has been investigated. Sim-
ulations reproduced experimental β+ emitting isotopes pro-
duction rates within an accuracy of 24%, and the production
rate change as a function of depth agreed well with experi-
mental data. By tuning the tolerance factor of the photon evap-
oration model available in GEANT4, an excellent agreement
between simulated and experimental prompt γ -ray produc-
tion rates was also achieved.
For this PET-based particle therapy monitoring applica-
tion, a confounding factor is introduced by the biological
washout through the blood flow of the induced β+ emit-
ters. The biological washout processes have been incorpo-
rated into GATE (WashoutActor) and will be available in
GATE V7. In particular, the model proposed by Mizuno et al.
has been implemented.129 This model accounts for the dis-
placement of the β+ emitters due to the blood flow, the mi-
crocirculation and the trapping of the radioisotopes by stable
molecules. Biological studies to further improve the modeling
of the washout processes implemented in GATE are currently
in progress. The influence of these effects on the measured
PET activity distributions is being studied.
Recently,130 introduced GEANT4 simulated β+ emitter
distributions as inputs for the EGS4 simulation code. This lat-
ter code was used to analyze and optimize the parameters of
a partial ring scanner suitable for inbeam PET. No informa-
tion regarding the physical models used in the GEANT4 sim-
ulations was given. The authors concluded that with 600 ps
timing resolution, at least an angular acceptance of 4π /3 was
required to achieve satisfactory estimate of the proton range.
3.F.3. Prompt-gamma studies
PG imaging is another approach currently explored to
monitor dose deposition in hadrontherapy.5, 6, 131 To our
knowledge only one paper using GATE has been published
so far in this area,132 but several GEANT4 studies have been
used and give indications regarding the potential of GATE for
such simulations.
In Ref. 132, the authors proposed a machine learning
approach based on GATE simulations to create optimized
treatment-specific classifiers that detect discrepancies be-
tween planned and delivered dose. The proposed method
could help to evaluate performance and to optimize the de-
sign of PG monitoring devices.
Several GEANT4 studies regarding PG imaging-based
hadron therapy monitoring focused on the investigation of
the GEANT4 accuracy to model prompt gamma emissions.
In Ref. 131, prompt gamma energy spectra acquired using
a high-purity germanium detector shielded either with lead
(passive shielding) or with a Compton suppression system
(active shielding) were compared to simulated spectra for a
proton irradiation. Results showed that GEANT4 properly
predicted the oxygen, carbon, and calcium emission lines.
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However, a precise modeling of the detector electronic, lack-
ing in the paper, was needed to correctly reproduce the mea-
surements for low energies. In Ref. 133, time-energy spectra
corresponding to the irradiation of PMMA and water targets
by monoenergetic carbon ions were acquired at the GSI and
GANIL facilities with collimated scintillators (BaF2 or NaI)
and compared with spectra simulated using GEANT4 V9.1
(Binary Cascade model). The simulations overestimated the
prompt-gamma detection yields by a factor of 12, highlighting
the need for an improvement of the GEANT4 de-excitation
models. Recent results, obtained with GEANT4 V9.4
(Ref. 134) are more promising, but the prompt gamma yield
was still overestimated by a factor of 2.
Although an extensive validation of GEANT4 is still
needed to fully trust results in terms of prompt gamma emis-
sion predictions, GEANT4 simulations have also been used
to investigate the feasibility of new systems to image prompt-
gamma profiles using Compton camera techniques135–137 or
mechanical collimators such as knife-edge slits and multi-
parallel slits.138, 139 A time-resolved simulation was recently
published exploring the potential use of time-of-flight rejec-
tion to suppress the background signal created by neutrons in
prompt-gamma imaging.140 To compare pros and cons of PET
and gamma prompt imaging,141 used GEANT4 V9.0 to study
four patient cases treated for head and neck, prostate, spine,
and abdomen cancers by proton therapy. The authors analyzed
production yields of particles of interest as well as emission
maps corresponding to prompt gammas and positron emit-
ters. The biological washout was modeled. Results suggested
that when accounting for washout correction and acquisi-
tion time delay, production yields corresponding to prompt-
gammas were 60–80 times higher than rates of annihilation
photons. For both PET and prompt-gammas, the correlation
between the fall-off of the profiles of the secondary particles
and the fall-off of the dose was especially intricate. The au-
thors concluded that checking the accuracy of dose deposit
only based on the imaging signal (without referring to sim-
ulations) would be extremely challenging, and that the sim-
ulation of the secondary particle distribution was needed to
conclude at the accuracy of the dose delivery with respect
to the treatment plan. These GEANT4 results illustrate the
type of study that could be conducted with GATE, with the
possibility of precisely and easily modeling highly realistic
imaging devices. The importance of precise modeling of the
detailed features of the imaging devices for ensuring accu-
rate predictions from the simulations has been demonstrated
in Ref. 123.
Simulations are also used to explore the feasibility of orig-
inal methods for image-based hadrontherapy monitoring. In
Ref. 7, imaging of secondary protons performed during car-
bon ion irradiations was investigated. Two detection tech-
niques were studied: the double-proton detection using two
forward-located trackers and the single-proton detection in
coincidence with the incoming carbon ion detected by means
of a beam hodoscope.
Last, some studies only focus on the validation of the
GEANT4 hadronic models in the context of image-based ther-
apy monitoring, without considering a specific imaging tech-
nique. In Ref. 142, the results obtained with the nuclear mod-
els implemented in GATE/GEANT4 and FLUKA were com-
pared by analyzing the angular and energy distributions of
secondary particles exiting a homogeneous target of PMMA
for a proton and a C12 beam. Despite the very simple tar-
get and set-up, substantial discrepancies were observed be-
tween the two codes, especially in terms of produced high
energy (>1 MeV) prompt gammas whatever the beam and in
term of exiting neutrons for the proton beam. All these results
call for further investigation of the physics models and of the
impact these models have on the simulated data. Along the
same line, but at the GEANT4 level only,143 analyzed integral
and differential yields of secondary fragments produced dur-
ing carbon ion irradiations. The yields were simulated using
GEANT4 (Binary Cascade and Quantum Molecular Dynam-
ics models) and FLUKA MC codes. A reasonable accuracy
was obtained for integrated yields but results suggested that
hadronic models of GEANT4 should be improved to correctly
reproduce secondary fragment angular distributions. The use
of the QMD model to handle ion–ion interactions was also
recommended.
A meta-analysis of the results related to the use of
GEANT4 for hadrontherapy applications led to the defi-
nition of optimized GEANT4 physics lists and parameter
settings relevant for imaging-based dose verification meth-
ods in hadrontherapy. The parameter settings can be found
on the GATE website (http://www.opengatecollaboration.org/
UsersGuide).
4. DISCUSSION AND CONCLUSION
To further illustrate our review, we provided access to
ready-to-use examples of realistic GATE simulations that
include particle tracking in voxelized phantoms based on
CT images and aim to provide 3D dose distributions. Five
examples corresponding to EBRT (both photon and elec-
tron beams), brachytherapy, protontherapy, and molecular
RT (MRT) are detailed on the web page of the Open-
Gate collaboration19 (http://wiki.opengatecollaboration.org/
DosiGate). Such examples might guide potential users in the
settings of a specific simulation and are used by GATE de-
velopers to monitor changes in results introduced by changes
in GEANT4 and in GATE versions. All examples were run
on the same computer (single core Intel Xeon CPU E5-1660
3.3 GHz), and Table I summarizes the number of tracks gen-
erated by primary particles (events), the total number of steps
(all particles included), the ratio between the numbers of geo-
metrical steps (limited by a geometrical boundary) and phys-
ical steps (limited by a physical process), the approximate
number of primary events needed to reach 2% statistical un-
certainty in the target, the number of particle per seconds
and the total simulation time. Results show that the com-
puting time strongly depends on the physics involved in the
simulation. For example, the protontherapy case produced 50
times more particles than the brachytherapy case. Also the
ratio between the numbers of geometrical steps and physical
steps depends on the energy and type of particles. To the best
of our knowledge, this is the first time such a comparative
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TABLE I. Simulation features and time durations for four examples of GATE
simulations available online. Columns are: “tracks by p.” is the mean number
of tracks by primary particle, “Steps by p.” is the mean number of steps by
primary particle, “Steps phy/geo” is the ratio between the geometrical and
physical steps, “uncert 2%” is the (approximate) number of primary particles
needed to reach 2% statistical uncertainty in the target region, “PPS” is the
number of particles per seconds, and “Time” the total needed time to reach
2% statistical uncertainty.
Tracks Steps Steps Uncert.
Example by p. by p. phy/geo 2% PPS Time
EBRT photon 2.6 198 0.5 6e7 6300 2.7 h
EBRT electron 28.6 429 16 2e8 500 4.6 j
Brachytherapy 1.0 25 0.07 5e7 20 000 45 min
Protontherapy 58 535 8.23 3e6 270 3.1 h
Molecular RT 1.8 65 0.55 2e8 3500 16 h
analysis between different applications, using the same code
and the same computer, is presented. It illustrates the compu-
tation time to be expected for a given application.
To obtain absorbed dose uncertainties below few percent in
MRT dosimetry it is typically necessary to simulate about ten
times the primary particles needed to obtain similar uncertain-
ties in EBRT. The reason is mainly related to the different ge-
ometries of the radiation sources: while in EBRT the radiation
source is well collimated, and the absorbed dose calculation
is restricted to a relatively small region, in MRT the source
distribution is usually heterogeneous and spread throughout
the patient body. The dosimetry of organs with (source) and
without (target) specific uptake is of equal importance. In tar-
get organs the absorbed dose is mainly due to photons gener-
ated in source organs. Since for ballistic reasons only a small
percentage of the emitted photon radiation reaches the tar-
get organs, the simulation statistics in these regions converge
slowly.
The ability of GATE to easily design both imaging and
dosimetry simulations in the same framework is of paramount
importance in molecular dosimetry as activity quantification
is a prerequisite to absorbed dose calculation. It is now possi-
ble to consider the simulation of a complete clinical dosime-
try study (i.e., from image generation to absorbed dose maps
calculation) with the same MC code. This is the aim of a
currently ongoing project, DosiTest,69 for which the com-
bined modeling of imaging and dosimetry is essential. Sim-
ilarly, the fact that GATE supports both imaging and RT
modeling makes it especially suitable for investigating the
emerging field of in vivo dose delivery monitoring in hadron-
therapy. Here, GATE may play an important role in the
development of dedicated devices for imaging the secondary
radiations induced by therapeutic hadrons within the patient.
Moreover, the correlation of the dose distribution and the sec-
ondary emission reference map on a per-patient basis within
a single, user-friendly software framework might prove to be
crucial in the clinical evaluation and application of these new
RT monitoring approaches.
Although GATE is mostly known for its imaging applica-
tions so far, this review aimed at demonstrating its versatility
and potentials for dosimetry and radiotherapy applications,
based on an already significant amount of results and vali-
dation studies. Being an open-source, user-friendly and inte-
grated tool enabling simulations of RT, dosimetry and imag-
ing in the very same framework, it is expected that GATE
will play an increasing role in the emerging domain of com-
bined imaging and therapy. Advanced users are welcome to
contribute to the source code.
To best meet the needs prompted by these new appli-
cations, developments by the OpenGATE collaboration are
ongoing. A release supporting CPU and GPU architectures
for specific applications (PET and photon RT) is being
prepared.35 Work is also in progress to include forced detec-
tion in GATE for kV imaging. Speeding up GATE simulations
is also considered by combining MC and analytic algorithms
within GATE,34 first for absorbed dose distribution of low en-
ergy beams (imaging, synchrotron treatments, small animal
treatments).
ACKNOWLEDGMENTS
This work was supported in part by the European col-
laboration Envision (Grant Agreement No. 241851), the
IMADRON project from INCa, the Labex PRIMES (ANR-
11-LABX-0063) of Université de Lyon within the program
“Investissements d’Avenir” (ANR-11-IDEX-0007) operated
by the French National Research Agency (ANR), the Lyric
grant INCa-DGOS-4664, the DOSEVAL grant (INCa).
a)Author to whom correspondence should be addressed. Electronic mail:
david.sarrut@creatis.insa-lyon.fr
1N. Reynaert, S. Vandermarck, D. Schaart, W. Vanderzee, C. Vanvli-
etvroegindeweij, M. Tomsej, J. Jansen, B. Heijmen, M. Coghe, and
C. Dewagter, “Monte carlo treatment planning for photon and electron
beams,” Radiat. Phys. Chem. 76, 643–686 (2007).
2M. J. Murphy, J. M. Balter, S. Balter, J. A. BenComo, I. J. Das, S. B. Jiang,
C.-M. Ma, G. H. Olivera, R. F. Rodebaugh, K. J. Ruchala, H. Shirato,
and F.-F. Yin, “The management of imaging dose during image-guided
radiotherapy: Report of the AAPM Task Group 75,” Med. Phys. 34, 4041–
4063 (2007).
3X. Zhu, S. España, J. Daartz, N. Liebsch, J. Ouyang, H. Paganetti,
T. R. Bortfeld, and G. El Fakhri, “Monitoring proton radiation therapy
with in-room PET imaging,” Phys. Med. Biol. 56, 4041–4057 (2011).
4K. Parodi, T. Bortfeld, and T. Haberer, “Comparison between in-beam and
offline positron emission tomography imaging of proton and carbon ion
therapeutic irradiation at synchrotron- and cyclotron-based facilities,” Int.
J. Radiat. Oncol., Biol., Phys. 71, 945–956 (2008).
5C.-H. Min, C. H. Kim, M.-Y. Youn, and J.-W. Kim, “Prompt gamma mea-
surements for locating the dose falloff region in the proton therapy,” Appl.
Phys. Lett. 89, 183517 (2006).
6E. Testa, M. Bajard, M. Chevallier, D. Dauvergne, F. Le Foulher, N. Freud,
J. Létang, J. Poizat, C. Ray, and M. Testa, “Monitoring the bragg peak
location of 73 MeV/u carbon ions by means of prompt gamma-ray mea-
surements,” Appl. Phys. Lett. 93, 093506 (2008).
7P. Henriquet, E. Testa, M. Chevallier, D. Dauvergne, G. Dedes, N. Freud,
J. Krimmer, J. M. Létang, C. Ray, M.-H. Richard, and F. Sauli, “Interac-
tion vertex imaging (IVI) for carbon ion therapy monitoring: A feasibility
study,” Phys. Med. Biol. 57, 4655–4669 (2012).
8M. Ljungberg and S. E. Strand, “A Monte Carlo program for the simu-
lation of scintillation camera characteristics,” Comput Methods Programs
Biomed 29, 257–272 (1989).
9R. Harrison and S. Vannoy, “Preliminary experience with the photon his-
tory generator module of a public-domain simulation system for emission
tomography,” in Proceedings of the IEEE Nuclear Science Symposium and
Medical Imaging Conference (1993), pp. 1154–1158.
Medical Physics, Vol. 41, No. 6, June 2014
064301-11 Sarrut et al.: GATE for dosimetry 064301-11
10M. Cañadas, P. Arce, and P. Rato Mendes, “Validation of a small-animal
pet simulation using gamos: A GEANT4-based framework,” Phys. Med.
Biol. 56, 273–288 (2011).
11LANL, MCNPX 2.6.0 Users’s Guide, Technical Report No. LA-CP-07
1473, 2008.
12G. Battistoni, S. Muraro, P. Sala, F. Cerutti, A. Ferrari, S. Roesler,
A. Fasso, and J. Ranft, “The FLUKA code: Description and benchmark-
ing,” in Hadronic Shower Simulations Workshop, edited by M. Albrow
and R. Raja (AIP Conference, Fermilab, Batavia, IL, 2006), Vol. 896, pp.
31–49.
13A. Ferrari, P. Sala, A. Fasso, and J. Ranft, FLUKA: A Multi-Particle Trans-
port Code, Technical Report No. INFN/TC 05/11, SLAC-R-773, CERN-
2005-10, 2005.
14J. Perl, J. Shin, B. Faddegon, and H. Paganetti, “TOPAS: An innovative
proton Monte Carlo platform for research,” Med. Phys. 39, 6818–6837
(2012).
15B. R. B. Walters, I. Kawrakow, and D. W. O. Rogers, “History by history
statistical estimators in the beam code system,” Med. Phys. 29, 2745–2752
(2002).
16I. Kawrakow and M. Fippel, “Investigation of variance reduction tech-
niques for Monte Carlo photon dose calculation using XVMC,” Phys.
Med. Biol. 45, 2163–2183 (2000).
17S. Jan, G. Santin, D. Strul, S. Staelens, K. Assié, D. Autret, S. Avner,
R. Barbier, M. Bardiès, P. M. Bloomfield, D. Brasse, V. Breton, P. Bruyn-
donckx, I. Buvat, A. F. Chatziioannou, Y. Choi, Y. H. Chung, C. Com-
tat, D. Donnarieix, L. Ferrer, S. J. Glick, C. J. Groiselle, D. Guez,
P.-F. F. Honore, S. Kerhoas-Cavata, A. S. Kirov, V. Kohli, M. Koole,
M. Krieguer, D. J. V. D. Laan, F. Lamare, G. Largeron, C. Lartizien,
D. Lazaro, M. C. Maas, L. Maigne, F. Mayet, F. Melot, C. Merheb, E. Pen-
nacchio, J. Perez, U. Pietrzyk, F. R. Rannou, M. Rey, D. R. Schaart,
C. R. Schmidtlein, L. Simon, T. Y. Song, J.-M. M. Vieira, D. Visvikis,
R. V. D. Walle, E. Wieërs, C. Morel, K. Assie, M. Bardies, D. J. van der
Laan, R. Van de Walle, and E. Wieers, “Gate: A simulation toolkit for PET
and SPECT,” Phys. Med. Biol. 49, 4543–4561 (2004).
18S. Jan, D. Benoit, E. Becheva, T. Carlier, F. Cassol, P. Descourt, T. Fris-
son, L. Grevillot, L. Guigues, L. Maigne, C. Morel, Y. Perrot, N. Rehfeld,
D. Sarrut, D. R. Schaart, S. Stute, U. Pietrzyk, D. Visvikis, N. Zahra, and
I. Buvat, “GATE V6: A major enhancement of the gate simulation plat-
form enabling modelling of CT and radiotherapy,” Phys. Med. Biol. 56,
881–901 (2011).
19The OpenGate Collaboration, http://www.opengatecollaboration.org,
2014.
20The OpenGate Collaboration, http://git.opengatecollaboration.org/git/
opengate-public.git, 2014.
21I. J. Chetty, M. Rosu, M. L. Kessler, B. A. Fraass, R. K. Ten Haken,
F.-M. S. Kong, and D. L. McShan, “Reporting and analyzing statistical
uncertainties in Monte Carlo-based treatment planning,” Int. J. Radiat.
Oncol., Biol., Phys. 65, 1249–1259 (2006).
22H. Paganetti, “Dose to water versus dose to medium in proton beam ther-
apy,” Phys. Med. Biol. 54, 4399–4421 (2009).
23L. Grevillot, D. Bertrand, F. Dessy, N. Freud, and D. Sarrut, “Gate as a
GEANT4-based Monte Carlo platform for the evaluation of proton pencil
beam scanning treatment plans,” Phys. Med. Biol. 57, 4223–4244 (2012).
24Å. C. Tedgren and G. A. Carlsson, “Specification of absorbed dose to wa-
ter using model-based dose calculation algorithms for treatment planning
in brachytherapy,” Phys. Med. Biol. 58, 2561–2579 (2013).
25H. Jiang and H. Paganetti, “Adaptation of GEANT4 to Monte Carlo dose
calculations based on CT data,” Med. Phys. 31, 2811–2818 (2004).
26H. Jiang, J. Seco, and H. Paganetti, “Effects of Hounsfield number con-
version on CT based proton Monte Carlo dose calculations,” Med. Phys.
34, 1439–1449 (2007).
27W. Schneider, T. Bortfeld, and W. Schlegel, “Correlation between CT
numbers and tissue parameters needed for Monte Carlo simulations of
clinical dose distributions,” Phys. Med. Biol. 45, 459–478 (2000).
28D. Sarrut and L. Guigues, “Region-oriented CT image representation for
reducing computing time of Monte Carlo simulations,” Med. Phys. 35,
1452–1463 (2008).
29L. Grevillot, T. Frisson, D. Maneval, N. Zahra, J. Badel, and D. Sar-
rut, “Simulation of a 6 MV Elekta Precise linac photon beam using
GATE/GEANT4,” Phys. Med. Biol. 56, 903–918 (2011).
30N. S. Rehfeld, S. Stute, J. Apostolakis, M. Soret, and I. Buvat, “Introduc-
ing improved voxel navigation and fictitious interaction tracking in gate
for enhanced efficiency,” Phys. Med. Biol. 54, 2163–2178 (2009).
31J. J. DeMarco, I. J. Chetty, and T. D. Solberg, “A Monte Carlo tutorial and
the application for radiotherapy treatment planning,” Med. Dosim. 27, 43–
50 (2002).
32A. Mittone et al., “An efficient numerical tool for dose deposition pre-
diction applied to synchrotron medical imaging and radiation therapy,” J.
Synchrotron Radiat. 20, 785–792 (2013).
33G. Poludniowski, P. M. Evans, V. N. Hansen, and S. Webb, “An efficient
Monte Carlo-based algorithm for scatter correction in keV cone-beam
CT,” Phys. Med. Biol. 54, 3847–3864 (2009).
34F. Smekens, N. Freud, J. M. Létang, J.-F. Adam, C. Ferrero, H. Elleaume,
A. Bravin, F. Estève, and D. Babot, “Simulation of dose deposition in
stereotactic synchrotron radiation therapy: A fast approach combining
Monte Carlo and deterministic algorithms,” Phys. Med. Biol. 54, 4671–
4685 (2009).
35J. Bert, H. Perez-Ponce, Z. E. Bitar, S. Jan, Y. Boursier, D. Vintache,
A. Bonissent, C. Morel, D. Brasse, and D. Visvikis, “GEANT4-based
Monte Carlo simulations on GPU for medical applications,” Phys. Med.
Biol. 58, 5593–5611 (2013).
36M. J. Berger, Improved Point Kernels for Electron and Beta-Ray Dosime-
try (US Department of Commerce, National Bureau of Standards NBSIR,
Washington DC, 1973), pp. 73–107.
37D. J. Simpkin and T. R. Mackie, “EGS4 Monte Carlo determination of the
beta dose kernel in water,” Med. Phys. 17, 179–186 (1990).
38M. Bardiès, C. S. Kwok, and G. Sgouros, “Dose point-kernel for radionu-
clide dosimetry,” in Therapeutic Applications of Monte Carlo Calcula-
tions in Nuclear Medicine, edited by H. Zaidi and G. Sgouros (Institute of
Physics Publishing, London, 2002), Chap. 7.
39H. Uusijarvi, N. Chouin, P. Bernhardt, L. Ferrer, M. Bardies, and
E. Forssell-Aronsson, “Comparison of electron dose-point kernels in wa-
ter generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX,
and ETRAN,” Cancer Biother. Radiopharm. 24, 461–467 (2009).
40F. Botta, A. Mairani, G. Battistoni, M. Cremonesi, A. Di Dia, A. Fasso,
A. Ferrari, M. Ferrari, G. Paganelli, G. Pedroli, and M. Valente, “Calcu-
lation of electron and isotopes dose point kernels with FLUKA Monte
Carlo code for dosimetry in nuclear medicine therapy,” Med. Phys. 38,
3944–3954 (2011).
41J. Seco and F. Verhaegen, Monte Carlo Techniques in Radiation Therapy
(CRC Press, 2013), Chap. 15, p. 223.
42L. Ferrer, N. Chouin, A. Bitar, A. Lisbona, and M. Bardies, “Implementing
dosimetry in GATE: dose-point kernel validation with GEANT4 4.8.1,”
Cancer Biother. Radiopharm. 22, 125–129 (2007).
43L. Maigne, Y. Perrot, D. R. Schaart, D. Donnarieix, and V. Breton, “Com-
parison of GATE/GEANT4 with EGSnrc and MCNP for electron dose
calculations at energies between 15 keV and 20 MeV,” Phys. Med. Biol.
56, 811–827 (2011).
44D. R. Schaart, J. T. M. Jansen, J. Zoetelief, and P. F. A. de Leege, “A
comparison of MCNP4C electron transport with ITS 3.0 and experiment
at incident energies between 100 keV and 20 MeV: Influence of voxel size,
substeps and energy indexing algorithm,” Phys. Med. Biol. 47, 1459–1484
(2002).
45G. Loudos, I. Tsougos, S. Boukis, N. Karakatsanis, P. Georgoulias,
K. Theodorou, K. Nikita, and C. Kappas, “A radionuclide dosimetry
toolkit based on material-specific Monte Carlo dose kernels,” Nucl. Med.
Commun. 30, 504–512 (2009).
46P. Papadimitroulas, G. Loudos, G. Nikiforidis, and G. Kagadis, “A dose
point kernel database using GATE Monte Carlo simulation toolkit for nu-
clear medicine applications: Comparison with other Monte Carlo codes,”
Med. Phys. 39, 5238–5247 (2012).
47E. Amato, A. Italiano, F. Minutoli, and S. Baldari, “Use of the GEANT4
Monte Carlo to determine three-dimensional dose factors for radionu-
clide dosimetry,” Nucl. Instrum. Methods Phys. Res., Sect. A 708, 15–18
(2013).
48N. Chouin, K. Bernardeau, F. Davodeau, M. Cherel, A. Faivre-
Chauvet, M. Bourgeois, C. Apostolidis, A. Morgenstern, A. Lisbona, and
M. Bardies, “Evidence of extranuclear cell sensitivity to alpha-particle ra-
diation using a microdosimetric model. I. Presentation and validation of a
microdosimetric model,” Radiat. Res. 171, 657–663 (2009).
49L. Thijssen, D. R. Schaart, D. de Vries, A. Morgenstern, F. Bruchertseifer,
and A. G. Denkova, “Polymersomes as nano-carriers to retain harmful
recoil nuclides in alpha radionuclide therapy: A feasibility study,” Ra-
diochim. Acta 100, 473–482 (2012).
50S. Incerti, A. Ivanchenko, M. Karamitros, A. Mantero, P. Moretto,
H. N. Tran, B. Mascialino, C. Champion, V. N. Ivanchenko, M. A. Bernal,
Medical Physics, Vol. 41, No. 6, June 2014
064301-12 Sarrut et al.: GATE for dosimetry 064301-12
Z. Francis, C. Villagrasa, G. Baldacchino, P. Gueye, R. Capra, P. Niemi-
nen, and C. Zacharatou, “Comparison of GEANT4 very low energy cross
section models with experimental data in water,” Med. Phys. 37, 4692–
4708 (2010).
51C. Villagrasa, Z. Francis, and S. Incerti, “Physical models implemented
in the GEANT4-DNA extension of the GEANT4 toolkit for calculating
initial radiation damage at the molecular level,” Radiat. Protect. Dosim.
143, 214–218 (2011).
52R. Loevinger, T. Budinger, and E. Watson, MIRD Primer for Absorbed
Dose Calculations. Revised, Technical Report (The Society of Nuclear
Medicine, New York, 1991).
53M. Stabin, “Nuclear medicine dosimetry,” Phys. Med. Biol. 51, R187–
R202 (2006).
54M. G. Stabin, M. A. Emmons, W. P. Segars, and M. J. Fernald, “Realis-
tic reference adult and paediatric phantom series for internal and external
dosimetry,” Radiat. Protect. Dosim. 149, 56–59 (2012).
55M. A. Keenan, M. G. Stabin, W. P. Segars, and M. J. Fernald, “RADAR
realistic animal model series for dose assessment,” J. Nucl. Med. 51, 471–
476 (2010).
56R. Taschereau and A. F. Chatziioannou, “Monte Carlo simulations of ab-
sorbed dose in a mouse phantom from 18-fluorine compounds,” Med.
Phys. 34, 1026–1036 (2007).
57W. Segars, B. Tsui, and E. Frey, “Development of a 4D digital mouse
phantom for molecular imaging research,” Mol. Imaging Biol. 6, 149–159
(2004).
58T. Mauxion, J. Barbet, J. Suhard, J.-P. Pouget, M. Poirot, and M. Bardiès,
“Improved realism of hybrid mouse models may not be sufficient to gen-
erate reference dosimetric data,” Med. Phys. 40, 052501 (11pp.) (2013).
59T. Mauxion, J. Barbet, J. Suhard, and M. Bardiès, “Validation of a scaled
digital phantom Moby based on 18F S-values calculation with Monte
Carlo codes GATE v6.1 and MCNPX v2.7,” in Proceedings of the Eu-
ropean Association of Nuclear Medicine Congress, 2012.
60T. Mauxion, J. Barbet, J. Suhard, and M. Bardiès, “Reference rodent S-
values based on Monte Carlo simulation with GATE (v6.1) for radionu-
clides of interest in μ-PET imaging,” in Proceedings of the European As-
sociation of Nuclear Medicine Congress, 2012.
61C. Williams, D. Burckhardt, and J. Engdahl, “Evaluation and validation
of GATE-based absorbed dose calculation for 3D patient-specific internal
dosimetry,” Med. Phys. 33, 2098 (2006).
62A. A. Parach, H. Rajabi, and M. A. Askari, “Assessment of MIRD data for
internal dosimetry using the GATE Monte Carlo code,” Radiat. Environ.
Biophys. 50, 441–450 (2011).
63W. S. Snyder, H. L. Fisher, M. R. Ford, and G. G. Warner, “Estimates
of absorbed fractions for monoenergetic photon sources uniformly dis-
tributed in various organs of a heterogeneous phantom,” J. Nucl. Med. 3,
7–52 (1969).
64S. Chiavassa, M. Bardies, F. Guiraud-Vitaux, D. Bruel, J. R. Jourdain,
D. Franck, and I. Aubineau-Laniece, “Oedipe: A personalized dosimetric
tool associating voxel-based models with mcnpx,” Cancer Biother. Radio-
pharm. 20, 325–332 (2005).
65M. G. Stabin and H. Yoriyaz, “Photon specific absorbed fractions calcu-
lated in the trunk of an adult male voxel-based phantom,” Health Phys. 82,
21–44 (2002).
66H. Yoriyaz, A. dos Santos, M. G. Stabin, and R. Cabezas, “Absorbed frac-
tions in a voxel-based phantom calculated with the MCNP-4B code,” Med.
Phys. 27, 1555–1562 (2000).
67I. Zubal, C. Harrell, and E. Smith, “Computerized three-dimensional seg-
mented human anatomy,” Med. Phys. 21, 298–305 (1994).
68E. Saeedzadeh, S. Sarkar, A. Abbaspour Tehrani-Fard, M. R. Ay,
H. R. Khosravi, and G. Loudos, “3D calculation of absorbed dose for 131I-
targeted radiotherapy: A Monte Carlo study,” Radiat. Protect. Dosim. 150,
298–305 (2012).
69D. Villoing, B. McParland, J. Suhard, L. Ferrer, and M. Bardiès, “Dosimet-
ric calculation with Monte Carlo simulation of a PET radiotracer: Compar-
ison between the standard and the personalized approach,” in Proceedings
of the European Association of Nuclear Medicine Congress, 2012.
70J. Seco and F. Verhaegen, “Monte Carlo methods and applications for
brachytherapy dosimetry and treatment planning,” Monte Carlo Tech-
niques in Radiation Therapy (CRC Press, 2013), Chap. 9, p. 125.
71M. J. Rivard, B. M. Coursey, L. A. DeWerd, W. F. Hanson, M. Saiful
Huq, G. S. Ibbott, M. G. Mitch, R. Nath, and J. F. Williamson, “Up-
date of AAPM Task Group No. 43 Report: A revised AAPM protocol for
brachytherapy dose calculations,” Med. Phys. 31, 633–674 (2004).
72L. Beaulieu, A. Carlsson Tedgren, J.-F. Carrier, S. D. Davis, F. Mour-
tada, M. J. Rivard, R. M. Thomson, F. Verhaegen, T. A. Wareing, and
J. F. Williamson, “Report of the task group 186 on model-based dose cal-
culation methods in brachytherapy beyond the tg-43 formalism: Current
status and recommendations for clinical implementation,” Med. Phys. 39,
6208–6236 (2012).
73J.-F. Carrier and L. Beaulieu, “Impact of interseed attenuation and tissue
composition for permanent,” Med. Phys. 33, 595–604 (2006).
74H. Afsharpour, M. D’Amours, B. Coté, J.-F. Carrier, F. Verhaegen, and
L. Beaulieu, “A Monte Carlo study on the effect of seed design on the in-
terseed attenuation in permanent prostate implants,” Med. Phys. 35, 3671–
3681 (2008).
75R. Nath, H. Amols, C. Coffey, D. Duggan, S. Jani, Z. Li, M. Schell,
C. Soares, J. Whiting, P. E. Cole, I. Crocker, and R. Schwartz, “Intravascu-
lar brachytherapy physics: Report of the AAPM Radiation Therapy Com-
mittee Task Group No. 60,” Med. Phys. 26, 119–152 (1999).
76S.-T. Chiu-Tsao, D. R. Schaart, C. G. Soares, and R. Nath, “Dose cal-
culation formalisms and consensus dosimetry parameters for intravascu-
lar brachytherapy dosimetry: Recommendations of the AAPM Therapy
Physics Committee Task Group No. 149,” Med. Phys. 34, 4126–4157
(2007).
77C. O. Thiam, V. Breton, D. Donnarieix, B. Habib, and L. Maigne, “Valida-
tion of a dose deposited by low-energy photons using GATE/GEANT4,”
Phys. Med. Biol. 53, 3039–3055 (2008).
78D. Granero, J. Pérez-Calatayud, F. Ballester, E. Casal, and J. M. De Fru-
tos, “Dosimetric study of the 15 mm ROPES eye plaque,” Med. Phys. 31,
3330–3336 (2004).
79J. Pérez-Calatayud, D. Granero, and F. Ballester, “Phantom size in
brachytherapy source dosimetric studies,” Med. Phys. 31, 2075–2081
(2004).
80J. Pérez-Calatayud, D. Granero, E. Casal, F. Ballester, and V. Puchades,
“Monte Carlo and experimental derivation of TG43 dosimetric parameters
for CSM-type Cs-137 sources,” Med. Phys. 32, 28–36 (2005).
81A. S. Meigooni, C. Wright, R. a. Koona, S. B. Awan, D. Granero, J. Perez-
Calatayud, and F. Ballester, “TG-43 U1 based dosimetric characterization
of model 67-6520 Cs-137 brachytherapy source,” Med. Phys. 36, 4711–
4712 (2009).
82S. S. O. Fonseca-Rodrigues, M. C. Martins, M. Begalli, P. P. Q. Filho,
and D. D. Souza-Santos, “Calculation of dosimetry parameters for 192Ir
and 125I brachytherapy sources using GEANT4,” in Proceeding of the
Nuclear Science Symposium Conference Record, 2010.
83S. S. O. Fonseca-Rodrigues, M. Begalli, P. P. Q. Filho, and D. Souza-
Santos, “Monte Carlo simulation of an Ir-192 brachytherapy source
spectra, geometry and anysotropy factors using GEANT4 code,” in
Proceeding of the Nuclear Science Symposium Conference Record,
2008.
84D. Granero, J. Pérez-Calatayud, and F. Ballester, “Monte Carlo calculation
of the TG-43 dosimetric parameters of a new BEBIG Ir-192 HDR source,”
Radiother. Oncol. 76, 79–85 (2005).
85D. Granero, J. Vijande, F. Ballester, and M. J. Rivard, “Dosimetry revisited
for the hdr 192Ir brachytherapy source model mHDR-v2,” Med. Phys. 38,
487–494 (2011).
86D. Granero, J. Pérez-Calatayud, E. Casal, F. Ballester, and J. Venselaar,
“A dosimetric study on the Ir-192 high dose rate flexisource,” Med. Phys.
33, 4578–4582 (2006).
87D. Granero, J. Pérez-Calatayud, J. Gimeno, F. Ballester, E. Casal,
V. Crispín, and R. Van Der Laarse, “Design and evaluation of a hdr skin
applicator with flattening filter,” Med. Phys. 35, 495–503 (2008).
88J. Pérez-Calatayud, D. Granero, F. Ballester, V. Crispín, and R. Van Der
Laarse, “Technique for routine output verification of leipzig applicators
with a well chamber,” Med. Phys. 33, 16–20 (2006).
89J. Pérez-Calatayud, D. Granero, F. Ballester, V. Puchades, E. Casal, A. So-
riano, and V. Crispín, “A dosimetric study of Leipzig applicators,” Int. J.
Radiat. Oncol., Biol., Phys. 62, 579–584 (2005).
90S. Enger, M. D’Amours, and L. Beaulieu, “Modeling a hypothetical
170Tm source for brachytherapy applications,” Med. Phys. 38, 5307–
5310 (2011).
91S. Enger, H. Lundqvist, M. D’Amours, and L. Beaulieu, “Exploring
(57)Co as a new isotope for brachytherapy applications,” Med. Phys. 39,
2342–2345 (2012).
92D. Liu, E. Poon, M. Bazalova, B. Reniers, M. Evans, T. Rusch, and F. Ver-
haegen, “Spectroscopic characterization of a novel electronic brachyther-
apy system,” Phys. Med. Biol. 53, 61–75 (2008).
Medical Physics, Vol. 41, No. 6, June 2014
064301-13 Sarrut et al.: GATE for dosimetry 064301-13
93G. Landry, B. Reniers, L. Murrer, L. Lutgens, E. Bloemen-Van Gurp, J.-
P. Pignol, B. Keller, L. Beaulieu, and F. Verhaegen, “Sensitivity of low
energy brachytherapy Monte Carlo dose calculations to uncertainties in
human tissue composition,” Med. Phys. 37, 5188–5198 (2010).
94G. Landry, P. V. Granton, B. Reniers, M. C. Öllers, L. Beaulieu, J. E. Wild-
berger, and F. Verhaegen, “Simulation study on potential accuracy gains
from dual energy CT tissue segmentation for low-energy brachytherapy
Monte Carlo dose calculations,” Phys. Med. Biol. 56, 6257 (2011).
95E. Poon, Y. Le, J. F. Williamson, and F. Verhaegen, “BrachyGUI: An ad-
junct to an accelerated Monte Carlo photon transport code for patient-
specific brachytherapy dose calculations and analysis,” J. Phys.: Conf. Ser.
102, 012018 (2008).
96H. Afsharpour, G. Landry, M. D’Amours, S. Enger, B. Reniers, E. Poon,
J.-F. Carrier, F. Verhaegen, and L. Beaulieu, “Algebra: Algorithm for the
heterogeneous dosimetry based on GEANT4 for brachytherapy,” Phys.
Med. Biol. 57, 3273–3280 (2012).
97J. Torres, M. J. Buades, J. F. Almansa, R. Guerrero, and A. M. Lallena,
“Dosimetry characterization of 32P intravascular brachytherapy source
wires using Monte Carlo codes PENELOPE and GEANT4,” Med. Phys.
31, 296–304 (2004).
98D. Bouzid, N. Boussion, S. Benhalouche, O. Pradier, A.-S. Lucia, and
D. Visvikis, “[simulation Monte Carlo sur GATE V6.1 d’un appareil per-
opératoire intrabeam pour le cancer du sein],” Cancer Radiothér. 16, 528–
529 (2012).
99J. Seco and F. Verhaegen, “Monte Carlo modeling of external photon
beams in radiotherapy,” Monte Carlo Techniques in Radiation Therapy
(CRC Press, 2013), Chap. 5, p. 63.
100M. Fragoso, I. Kawrakow, B. A. Faddegon, T. D. Solberg, and I. J. Chetty,
“Fast, accurate photon beam accelerator modeling using BEAMnrc: A
systematic investigation of efficiency enhancing methods and cross-
section data,” Med. Phys. 36, 5451–5466 (2009).
101L. Brualla, R. Palanco-Zamora, K.-P. Steuhl, N. Bornfeld, and W. Sauer-
wein, “Monte Carlo simulations applied to conjunctival lymphoma radio-
therapy treatment,” Strahlenther. Onkol. 187, 492–498 (2011).
102N. Chofor, D. Harder, K. Willborn, A. Rühmann, and B. Poppe, “Low-
energy photons in high-energy photon fields–Monte Carlo generated
spectra and a new descriptive parameter,” Z. Med. Phys. 21, 183–197
(2011).
103E. Sterpin, Y. Chen, Q. Chen, W. Lu, T. R. Mackie, and S. Vynck-
ier, “Monte Carlo-based simulation of dynamic jaws tomotherapy,” Med.
Phys. 38, 5230–5238 (2011).
104M. K. Fix, W. Volken, D. Frei, D. Frauchiger, E. J. Born, and P. Manser,
“Monte Carlo implementation, validation, and characterization of a 120
leaf MLC,” Med. Phys. 38, 5311–5320 (2011).
105J. Belec, N. Ploquin, D. J. La Russa, and B. G. Clark, “Position-
probability-sampled Monte Carlo calculation of VMAT, 3DCRT, step-
shoot IMRT, and helical tomotherapy dose distributions using BEAM-
nrc/DOSXYZnrc,” Med. Phys. 38, 948–960 (2011).
106B. Vanderstraeten, N. Reynaert, L. Paelinck, I. Madani, C. De Wagter,
W. De Gersem, W. De Neve, and H. Thierens, “Accuracy of patient
dose calculation for lung IMRT: A comparison of Monte Carlo, convolu-
tion/superposition, and pencil beam computations,” Med. Phys. 33, 3149–
3158 (2006).
107L. Grevillot, D. Bertrand, F. Dessy, N. Freud, and D. Sarrut, “A Monte
Carlo pencil beam scanning model for proton treatment plan simulation
using GATE/GEANT4,” Phys. Med. Biol. 56, 5203–5219 (2011).
108S. Benhalouche, S. Edel, D. Visvikis, O. Pradier, and N. Boussion, “Gate
Monte Carlo simulation of a 6 MV siemens oncor linear accelerator pho-
ton beam: Feasibility and preliminary dosimetric study,” Med. Phys. 38,
3655 (2011).
109L. Grevillot, T. Frisson, N. Zahra, D. Bertrand, F. Stichelbaut, N. Freud,
and D. Sarrut, “Optimization of GEANT4 settings for proton pencil beam
scanning simulations using GATE,” Nucl. Instrum. Meth. Phys. Res. Sect.
B 268, 3295–3305 (2010).
110H. Paganetti, “Four-dimensional Monte Carlo simulation of time-
dependent geometries,” Phys. Med. Biol. 49, N75 (2004).
111H. Paganetti, H. Jiang, S.-Y. Lee, and H. M. Kooy, “Accurate Monte Carlo
simulations for nozzle design, commissioning and quality assurance for a
proton radiation therapy facility,” Med. Phys. 31, 2107–2118 (2004).
112H. Paganetti, H. Jiang, J. A. Adams, G. T. Y. Chen, and E. Rietzel, “Monte
carlo simulations with time-dependent geometries to investigate effects of
organ motion with high temporal resolution,” Int. J. Radiat. Oncol., Biol.,
Phys. 60, 942–950 (2004).
113G. Cirrone, G. Cuttone, F. Di Rosa, S. Mazzaglia, F. Romano, A. Attili,
F. Bourhaleb, G. Russo, P. Kataniemi, A. Heikkinen, and F. Marchetto,
“Hadrontherapy: An open source, GEANT4-based application for proton-
ion therapy studies,” in Proceedings of the IEEE Nuclear Science Sympo-
sium Conference Record (NSS/MIC) (2009), p. 4186.
114M. Fippel, “Efficient particle transport simulation through beam modulat-
ing devices for Monte Carlo treatment planning,” Med. Phys. 31, 1235–
1242 (2004).
115M. Fippel and M. Soukup, “A Monte Carlo dose calculation algorithm for
proton therapy,” Med. Phys. 31, 2263–2273 (2004).
116M. Soukup, M. Fippel, and M. Alber, “A pencil beam algorithm for in-
tensity modulated proton therapy derived from Monte Carlo simulations,”
Phys. Med. Biol. 50, 5089–5104 (2005).
117S. W. Peterson, J. Polf, M. Bues, G. Ciangaru, L. Archambault, S. Bed-
dar, and A. Smith, “Experimental validation of a Monte Carlo proton ther-
apy nozzle model incorporating magnetically steered protons,” Phys. Med.
Biol. 54, 3217–3229 (2009).
118T. Inaniwa, T. Furukawa, Y. Kase, N. Matsufuji, T. Toshito, Y. Matsumoto,
Y. Furusawa, and K. Noda, “Treatment planning for a scanned carbon
beam with a modified microdosimetric kinetic model,” Phys. Med. Biol.
55, 6721–6737 (2010).
119Y. Jia, C. Beltran, D. J. Indelicato, S. Flampouri, Z. Li, and T. E. Merchant,
“Proton therapy dose distribution comparison between Monte Carlo and a
treatment planning system for pediatric patients with ependymoma,” Med.
Phys. 39, 4742–4747 (2012).
120K. Parodi, W. Enghardt, and T. Haberer, “In-beam pet measurements of
beta+ radioactivity induced by proton beams,” Phys. Med. Biol. 47, 21–
36 (2002).
121S. Agostinelli, “GEANT4: A simulation toolkit,” Nucl. Instrum. Meth.
Phys. Res. Sect. A 506, 250–303 (2003).
122J. Allison, K. Amako, J. Apostolakis, H. Araujo, P. Arce Dubois, M. Asai,
G. Barrand, R. Capra, S. Chauvie, R. Chytracek, G. Cirrone, G. Coop-
erman, G. Cosmo, G. Cuttone, G. Daquino, M. Donszelmann, M. Dres-
sel, G. Folger, F. Foppiano, J. Generowicz, V. Grichine, S. Guatelli,
P. Gumplinger, A. Heikkinen, I. Hrivnacova, A. Howard, S. Incerti,
V. Ivanchenko, T. Johnson, F. Jones, T. Koi, R. Kokoulin, M. Kossov,
H. Kurashige, V. Lara, S. Larsson, F. Lei, O. Link, F. Longo, M. Maire,
A. Mantero, B. Mascialino, I. McLaren, P. Mendez Lorenzo, K. Mi-
namimoto, K. Murakami, P. Nieminen, L. Pandola, S. Parlati, L. Per-
alta, J. Perl, A. Pfeiffer, M. Pia, A. Ribon, P. Rodrigues, G. Russo,
S. Sadilov, G. Santin, T. Sasaki, D. Smith, N. Starkov, S. Tanaka, E. Tch-
erniaev, B. Tome, A. Trindade, P. Truscott, L. Urban, M. Verderi, A. Walk-
den, J. Wellisch, D. Williams, D. Wright, and H. Yoshida, “GEANT4
developments and applications,” IEEE Trans. Nucl. Sci. 53, 270–278
(2006).
123S. Jan, T. Frisson, and D. Sarrut, “Gate simulation of 12C hadrontherapy
treatment combined with a PET imaging system for dose monitoring: A
feasibility study,” IEEE Trans. Nucl. Sci. 60, 423–429 (2013).
124C. Robert, N. Fourrier, D. Sarrut, S. Stute, P. Gueth, L. Grevillot, and
I. Buvat, “PET-based dose delivery verification in proton therapy: A GATE
based simulation study of five PET system designs in clinical conditions,”
Phys. Med. Biol. 58, 6867–6885 (2013).
125E. Seravalli, C. Robert, J. Bauer, F. Stichelbaut, C. Kurz, J. Smeets, C. Van
Ngoc Ty, D. R. Schaart, I. Buvat, K. Parodi, and F. Verhaegen, “Monte
Carlo calculations of positron emitter yields in proton radiotherapy,” Phys.
Med. Biol. 57, 1659–1673 (2012).
126I. Pshenichnov, I. Mishustin, and W. Greiner, “Distributions of positron-
emitting nuclei in proton and carbon-ion therapy studied with GEANT4,”
Phys. Med. Biol. 51, 6099–6112 (2006).
127S. España, X. Zhu, J. Daartz, G. El Fakhri, T. Bortfeld, and H. Paganetti,
“The reliability of proton-nuclear interaction cross-section data to predict
proton-induced pet images in proton therapy,” Phys. Med. Biol. 56, 2687–
2698 (2011).
128L. Lestand, G. Montarou, P. Force, and N. Pauna, “In-beam quality assur-
ance using induced β(+) activity in hadrontherapy: A preliminary physi-
cal requirements study using GEANT4,” Phys. Med. Biol. 57, 6497–6518
(2012).
129H. Mizuno, T. Tomitani, M. Kanazawa, A. Kitagawa, J. Pawelke,
Y. Iseki, E. Urakabe, M. Suda, A. Kawano, R. Iritani, S. Matsushita,
T. Inaniwa, T. Nishio, S. Furukawa, K. Ando, Y. K. Nakamura, T. Kanai,
and K. Ishii, “Washout measurement of radioisotope implanted by
radioactive beams in the rabbit,” Phys. Med. Biol. 48, 2269–2281
(2003).
Medical Physics, Vol. 41, No. 6, June 2014
064301-14 Sarrut et al.: GATE for dosimetry 064301-14
130S. Surti, W. Zou, M. E. Daube-Witherspoon, J. McDonough, and
J. S. Karp, “Design study of an in situ PET scanner for use in proton beam
therapy,” Phys. Med. Biol. 56, 2667–2685 (2011).
131J. C. Polf, S. Peterson, M. McCleskey, B. T. Roeder, A. Spiridon, S. Bed-
dar, and L. Trache, “Measurement and calculation of characteristic prompt
gamma ray spectra emitted during proton irradiation,” Phys. Med. Biol.
54, N519–N527 (2009).
132P. Gueth, D. Dauvergne, N. Freud, J. M. Létang, C. Ray, E. Testa, and
D. Sarrut, “Machine learning-based patient specific prompt-gamma dose
monitoring in proton therapy,” Phys. Med. Biol. 58, 4563–4577 (2013).
133F. Le Foulher, M. Bajard, M. Chevallier, D. Dauvergne, N. Freud, P. Hen-
riquet, S. Karkar, J. M. Létang, L. Lestand, R. Plescak, C. Ray, D. Schardt,
E. Testa, and M. Testa, “Monte Carlo simulations of prompt-gamma emis-
sion during carbon ion irradiation,” IEEE Trans. Nucl. Sci. 57, 2768–2772
(2010).
134Envision, ENVISION delivrable D3.1, Technical Report, 2012.
135M. Frandes, A. Zoglauer, V. Maxim, and R. Prost, “A tracking compton-
scattering imaging system for hadron therapy monitoring,” IEEE Trans.
Nucl. Sci. 57, 144–150 (2010).
136S. W. Peterson, D. Robertson, and J. Polf, “Optimizing a three-stage comp-
ton camera for measuring prompt gamma rays emitted during proton ra-
diotherapy,” Phys. Med. Biol. 55, 6841–6856 (2010).
137M.-H. Richard, D. Dauvergne, M. Dahoumane, N. Freud, P. Henriquet,
J. M. Létang, J. Krimmer, C. Ray, E. Testa, and A. H. Walenta, “Design of
a Compton camera for hadrontherapy on-line control using GEANT4,” in
Proceedings of the IEEE Nuclear Science Symposium and Medical Imag-
ing Conference, 2011.
138V. Bom, L. Joulaeizadeh, and F. Beekman, “Real-time prompt gamma
monitoring in spot-scanning proton therapy using imaging through a
knife-edge-shaped slit,” Phys. Med. Biol. 57, 297–308 (2012).
139P. Cambraia-Lopes, M. Pinto, H. Simões, A. Biegun, P. Dendooven,
D. Oxley, K. Parodi, D. Schaart, and P. Crespo, “Optimization of collima-
tor designs for real-time proton range verification by measuring prompt
gamma rays,” in Proceedings of the IEEE Nuclear Science Symposium
and Medical Imaging Conference, 2012.
140A. K. Biegun, E. Seravalli, P. C. Lopes, I. Rinaldi, M. Pinto, D. C. Ox-
ley, P. Dendooven, F. Verhaegen, K. Parodi, P. Crespo, and D. R. Schaart,
“Time-of-flight neutron rejection to improve prompt gamma imaging for
proton range verification: A simulation study,” Phys. Med. Biol. 57, 6429–
6444 (2012).
141M. Moteabbed, S. Espana, and H. Paganetti, “Monte Carlo patient study
on the comparison of prompt gamma and pet imaging for range verifica-
tion in proton therapy,” Phys. Med. Biol. 56, 1063–1082 (2011).
142C. Robert, G. Dedes, G. Battistoni, T. T. Böhlen, I. Buvat, F. Cerutti,
M. P. W. Chin, A. Ferrari, P. Gueth, C. Kurz, L. Lestand, A. Mairani,
G. Montarou, R. Nicolini, P. G. Ortega, K. Parodi, Y. Prezado, P. R. Sala,
D. Sarrut, and E. Testa, “Distributions of secondary particles in pro-
ton and carbon-ion therapy: A comparison between GATE/Geant4
and FLUKA Monte Carlo codes,” Phys. Med. Biol. 58, 2879–2899
(2013).
143T. Bohlen, F. Cerutti, M. Dosanjh, A. Ferrari, I. Gudowska, A. Mairani,
J. Quesada, and T. Böhlen, “Benchmarking nuclear models of FLUKA
and GEANT4 for carbon ion therapy,” Phys. Med. Biol. 55, 5833–5847
(2010).
Medical Physics, Vol. 41, No. 6, June 2014
